NLS Pharmaceutics Analyst Ratings
NLS Pharmaceutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/08/2022 | 352.08% | Maxim Group | → $4 | Upgrades | Hold → Buy |
| 11/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 09/06/2022 | 578.12% | Laidlaw & Co. | → $6 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1256.24% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 03/03/2021 | 804.16% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 12/08/2022 | 352.08% | Maxim集团 | → $4 | 升级 | 持有→购买 |
| 11/08/2022 | — | Maxim集团 | 评级下调 | 购买→Hold | |
| 09/06/2022 | 578.12% | 莱德劳公司 | → $6 | 开始承保 | →购买 |
| 03/12/2021 | 1256.24% | 布鲁克林资本 | → $12 | 开始承保 | →购买 |
| 03/03/2021 | 804.16% | Maxim集团 | → $8 | 开始承保 | →购买 |
What is the target price for NLS Pharmaceutics (NLSP)?
NLS制药公司(NLSP)的目标价是多少？
The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on December 8, 2022. The analyst firm set a price target for $4.00 expecting NLSP to rise to within 12 months (a possible 352.08% upside). 3 analyst firms have reported ratings in the last year.
马克西姆集团于2022年12月8日报道了NLS制药公司(纳斯达克代码：NLSP)的最新目标价。这家分析公司将目标价定为4美元，预计NLSP将在12个月内上涨至(可能上涨352.08%)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for NLS Pharmaceutics (NLSP)?
NLS制药公司(NLSP)的最新分析师评级是多少？
The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics upgraded their buy rating.
新星医药(纳斯达克代码：NLSP)的最新分析师评级由Maxim Group提供，新星制药上调了其买入评级。
When is the next analyst rating going to be posted or updated for NLS Pharmaceutics (NLSP)?
NLS制药(NLSP)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on December 8, 2022 so you should expect the next rating to be made available sometime around December 8, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与NLS制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。NLS制药的上一次评级是在2022年12月8日提交的，所以你应该预计下一次评级将在2023年12月8日左右提供。
Is the Analyst Rating NLS Pharmaceutics (NLSP) correct?
分析师对NLS制药公司(NLSP)的评级正确吗？
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a upgraded with a price target of $0.00 to $4.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.88, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的NLS制药(NLSP)评级被上调，目标价为0.00美元至4.00美元。NLS制药公司(NLSP)目前的交易价格为0.88美元，在分析师的预测范围内。